About Us
Our Overview
Overview
Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).
Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
Hit API products such as Bisoprolol and Dabigatran, have been commercialized in regulated markets and China. Qingmu is experienced on exporting API products to more than 40 countries and regions such as Japan, USA, Germany, Spain, the Netherlands, Russia, South Korea, Brazil, etc.
Focus on business in regulated markets, Qingmu was inspected and approved by US FDA, Korea MFDS, and China NMPA, and also approved by customer audit from China, Europe, USA and Japan, etc.
In 2021, Qingmu started the construction of new manufacturing site, it covers an area of about 166000m2 and predict to invest about USD80 million for phase I, the new site is expected to run by Q2 2025. With the capacity of two manufacturing sites, Qingmu will ensure the rapid increasing CDMO business and more commercial API products.
Our Overview
Overview
Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).
Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
Hit API products such as Bisoprolol and Dabigatran, have been commercialized in regulated markets and China. Qingmu is experienced on exporting API products to more than 40 countries and regions such as Japan, USA, Germany, Spain, the Netherlands, Russia, South Korea, Brazil, etc.
Focus on business in regulated markets, Qingmu was inspected and approved by US FDA, Korea MFDS, and China NMPA, and also approved by customer audit from China, Europe, USA and Japan, etc.
In 2021, Qingmu started the construction of new manufacturing site, it covers an area of about 166000m2 and predict to invest about USD80 million for phase I, the new site is expected to run by Q2 2025. With the capacity of two manufacturing sites, Qingmu will ensure the rapid increasing CDMO business and more commercial API products.
Our Culture AND SOCIAL RESPONSIBILITY
Our History
History
Passed the Korea MFDS virtual inspection
Approved by USFDA site inspection
Qingmu initiated plan of new manufacturing site
10 products including Bisoprolol Fumarate obtained GMP certificates from Chinese NMPA
Qingmu passed Chinese new version GMP site inspection
Sichuan Qingmu Pharmaceutical Co.,Ltd. was established
Chengdu Mingyang Pharmaceutical Co.,Ltd. was established
(predecessor of Qingmu)
